Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of BIOPOR.CO is 1.8 and suggests 59.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to